B Vikram¹*, L Shankar²*, J Capala³*, K Kandarpa⁴*, S Benedict⁵*, C Glide-Hurst⁶*, Y Xiao⁷*, (1) NIH, Bethesda, MD, (2) National Cancer Institute, Bethesda, MD, (3) National Cancer Institute, Bethesda, MD, (4) NIH, Southborough, MA, (5) UC Davis Cancer Center, Davis, CA, (6) University of Wisconsin, Middleton, WI, (7) University of Pennsylvania, Philadelphia, PA

• 
  B Vikram
• 
  L Shankar
• 
  J Capala
• 
  K Kandarpa
• 
  S Benedict
• 
  C Glide-Hurst
• 
  Y Xiao

• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  

TU-K-BRB-0 (Tuesday, 7/12/2022) 4:30 PM - 6:00 PM [Eastern Time (GMT-4)]

Ballroom B

Medical physics plays crucial roles in clinical trials in their design, quality assurance, and other NIH programs with an emphasis on medical physics science within clinical trials across various groups (CIRO, IROC, NRG Oncology, AAPM, ECOG-ACRIN). Other opportunities for medical physics engagement in NIH in general are also available. (NCI QIRT, NCI QIN, NCI IOTN, NCI RRP, NCI CIP, NIBIB MIDRC, etc.).

The topics will cover the vision for radiotherapy and imaging advancement, for clinical trials and clinical care. Theranostic clinical trials outlook will be discussed with the role of medical physics.

Specific involvement of medical physics in quality assurance guideline development from the center for innovation in radiation oncology will be demonstrated. The involvement includes development of guidelines and strategies to unify the dosimetry-specific aims and goals, recording and documentation for several new treatment delivery and imaging approaches, including adaptive radiation therapy, image guided brachytherapy, AI in treatment planning, and new and emerging imaging protocols.

How medical physicist can be involved in clinical trial design for new technologies will be discussed and illustrated. Examples of new and emerging technologies include MR-guided adaptive therapy, radiopharmaceutical therapy, spatially fractionated therapy, FLASH, and a wide array of AI and machine learning applications to imaging and treatment planning.

Learning Objectives:
1. Recognize opportunities for medical physics across NIH programs.
2. Understand the potential to contribute to new clinical trials through activities of CIRO, NRG Oncology.
3. Introduction to opportunities to interface with AAPM task groups for new technology implementation guidelines.
4. Understand strategies to develop, publish, and expedite medical physics dosimetry protocols and templates for new clinical trials.
5. Identify strategies to support clinical medical physicists for participation in clinical trials, including protocol development for new technologies.

Funding Support, Disclosures, and Conflict of Interest: 2U24CA180803-06(IROC), 2U10CA180868-06(NRG)

Handouts

• 175-63187-16291659-184070-263883028.pdf (Ying Xiao)
• 175-63189-16291659-193888.pdf (Lalitha Shankar)
• 175-63190-16291659-186697.pdf (Jacek Capala)
• 175-63188-16291659-186695-1200538713.pdf (Bhadrasain Vikram)
• 175-66934-16291659-193930.pdf (Kris Kandarpa)
• 175-63192-16291659-183111.pdf (Stanley Benedict)

Keywords

Not Applicable / None Entered.

Taxonomy

Not Applicable / None Entered.

Contact Email